Bevacizumab vs steroids for brain radiation injury
Treatments studied
Part of Brain & nervous system, Cancer, Injuries & trauma clinical trials.
This trial tests if bevacizumab works better than steroids for people with brain swelling caused by radiation. If you have this condition and meet certain health requirements, you may join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have brain swelling from radiation, confirmed by your doctor
- Your daily steroid dose is 1 mg or less for the past 8 weeks
- You can understand study instructions and consent
- You have not had bevacizumab in the last 6 months
- Your life expectancy is more than 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Avastin (bevacizumab) for people with brain swelling (radionecrosis) after radiation. It's for those whose symptoms don't get better with steroids or come back when steroids are reduced.
This trial tests combining a drug called bevacizumab with a focused radiation treatment for people with lung cancer that has spread to the brain. It compares this to the standard radiation approach, and aims to see which better preserves memory and controls tumors.
This trial tests a combination of a drug that stops blood vessel growth (bevacizumab), immunotherapy, and focused radiation to treat melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach shrinks tumors and improves outcomes.
This study compares two steroid medications to reduce brain swelling caused by cancer that has spread to the brain. You'll receive one of these steroids while undergoing radiation therapy, and researchers will track how well each helps your symptoms.
This Phase 2 study tests a protective approach using bevacizumab (a medicine that blocks VEGF) while doctors carefully increase the dose in people with glioblastoma. It’s meant to help control tumor growth and possibly reduce certain risks that can happen with blood-vessel–targeting treatments.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
Hear when a new Radiation Necrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.